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ABSTRACT
Synovial sarcoma (SS) is a recalcitrant subgroup of soft tissue sarcoma (STS). 
A tumor from a patient with high grade SS from a lower extremity was grown 
orthotopically in the right biceps femoris muscle of nude mice to establish a patient-
derived orthotopic xenograft (PDOX) mouse model. The PDOX mice were randomized 
into the following groups when tumor volume reached approximately 100 mm3: G1, 
control without treatment; G2, doxorubicin (DOX) (3 mg/kg, intraperitoneal [i.p.] 
injection, weekly, for 2 weeks; G3, rMETase (100 unit/mouse, i.p., daily, for 2 weeks); 
G4 DOX (3mg/kg), i.p. weekly, for 2 weeks) combined with rMETase (100 unit/
mouse, i.p., daily, for 2 weeks). On day 14 after treatment initiation, all therapies 
significantly inhibited tumor growth compared to untreated control, except DOX: 
(DOX: p = 0.48; rMETase: p < 0.005; DOX combined with rMETase < 0.0001). DOX 
combined with rMETase was significantly more effective than both DOX alone (p < 
0.001) and rMETase alone (p < 0.05). The relative body weight on day 14 compared 
with day 0 did not significantly differ between any treatment group or untreated 
control. The results indicate that r-METase can overcome DOX-resistance in this 
recalcitrant disease. 
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INTRODUCTION
Sarcoma is a group of 50 or more rare recalcitrant 
cancers [1]. In order to improve the outcome of sarcoma 
patients, we have developed patient-derived orthotopic 
xenograft (PDOX) models of the major sarcomas: soft-
tissue sarcoma [2–4], follicular dendritic-cell sarcoma [5], 
Ewing’s sarcoma [6–10], undifferentiated pleomorphic 
soft-tissue sarcoma [11, 12], osteosarcoma [13–16, 25], 
rhabdomyosarcoma [17, 18], leiomyosarcoma [19] 
and undifferentiated spindle-cell sarcoma (USCS) 
[20, 23, 26]. During the course of finding more efficacious 
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agents for this group of diseases, we have found that our 
developmental therapeutic, recombinant methioninase 
(rMETase), is active and can inhibit or arrest tumor growth 
and in combination with an appropriate chemotherapy 
drug, can regress the PDOX tumors [7, 21–26].
rMETase effectively reduced tumor growth of a 
DOX-resistant FUS-ERG Ewing’s sarcoma PDOX [6] 
compared to untreated control. The methionine level both 
of plasma and supernatants derived from sonicated tumors 
was lower in the rMETase group [7]. 
An undifferentiated spindle-cell sarcoma (USCS) 
PDOX model was treated with rMETase. rMETase 
inhibited tumor growth, measured by tumor volume, 
compared to untreated controls and first-line therapy 
doxorubicin (DOX). Tumor L-methionine levels were 
reduced after rMETase-treatment [26]. 
In a subsequent study, we determined the efficacy of 
rMETase in combination with DOX in a PDOX model of 
USCS. rMETase in combination with DOX could regress 
the USCS PDOX model [23]. 
Synovial sarcoma (SS) is an aggressive subtype 
that accounts for 10% to 20% of soft tissue sarcoma 
(STS) in the adolescent and young adult population [27]. 
Treatment for localized SS consists of a combination of 
surgery, radiotherapy and, in some cases, chemotherapy. 
Chemotherapy has a low response rate for metastatic 
disease [28]. Treatment is usually wide surgical excision 
with adjuvant or neoadjuvant therapy. In the present study, 
we determined if rMETase could overcome first-line 
DOX-resistance in a PDOX model of SS. 
RESULTS AND DISCUSSION
On day 14 after initiation, DOX (p = 0.48) was 
ineffective on the SS PDOX. rMETase (p < 0.005) 
inhibited tumor growth and DOX combined with rMETase 
(p < 0.0001) regressed tumor growth. DOX combined 
with rMETase was significantly more effective than 
both DOX alone (p < 0.001)  and rMETase alone (p < 
0.05) (Figures 1–3). The relative body weight on day 14 
compared with day 0 did not significantly differ between 
any treatment group (Figure 4). 
Histology
High-power photomicrographs of hemotoxylin 
and eosin (H&E)-stained sections of the original patient 
tumor showed cancer cells with hyperchromatic, enlarged 
nuclei. Mitotic figures and atypical cells are present 
(Figure 5A). A high-power view of the untreated SS 
PDOX model showed similar features, including cells 
with hyperchromatic and enlarged nuclei. Mitotic figures, 
including atypical forms, are also present (Figure 5B). 
Tumors treated with DOX comprised viable cells without 
apparent necrosis or inflammatory changes (Figure 5C). 
Tumors treated with rMETase show altered cancer-cell 
shape and some necrosis (Figure 5D). Tumors treated with 
DOX combined with rMETase have extensive necrosis 
(Figure 5E).
There was a statistically-significant difference in 
tumor growth between either the untreated control or 
the DOX-treated PDOX, on the one hand, and either the 
rMETase- or the combination of rMETase and DOX-
treated PDOX on the other. There was also a statistically-
significant difference between the rMETase-treated and 
the combination rMETase-treated and DOX-treated 
PDOX. During the treatment period, there was no body-
weight loss in any treated group. 
Methionine restriction of cancer results in an S/
G2-phase cell-cycle arrest that eventually leads to cancer-
cell death [29–31]. This is the probable mechanism for 
necrosis in the rMETase-treated PDOX which is further 
exacerbated by the addition of DOX to rMETase. 
Lung metastasis in the synovial sarcoma and its 
sensitivity to rMETase will be a topic for future study.
Our laboratory has developed PDOX mouse 
models of cancer for discovery of transformative 
therapy for recalcitrant cancer. The PDOX nude mouse 
model is established with the technique of surgical 
orthotopic implantation (SOI). These models include 
breast [32], ovarian [33], lung [34], cervical [35], 
colon [36–38], pancreatic [39–43] and stomach cancer 
[44], melanoma [21, 22, 24, 45–48] as well as sarcoma 
[2–20, 23, 25, 26]. The PDOX model, developed by our 
laboratory over the past 30 years, has many advantages 
over subcutaneous-transplant models which grow 
ectopically under the skin and rarely can metastasize [49]. 
We have recently demonstrated that rMETase is 
effective against a PDOX model of Ewing’s sarcoma [7]. 
We have also found rMETase to be effective in a PDOX 
model of DOX-resistant spindle cell sarcoma [26] and to 
overcome DOX-resistance in the spindle-cell sarcoma 
PDOX [23]. 
All PDOX models tested thus far, including 
those derived from Ewing’s sarcoma [7], osteosarcoma 
[15], spindle-cell sarcoma [23, 26], and melanoma 
[21, 22, 24] are very sensitive to rMETase, and 
in combination with first-line chemotherapy, 
rMETase can regress PDOX tumors. These results, 
in addition to extensive in vitro and in vivo cell line 
studies showing MET-dependence and response to 
rMETase or other means of MET-restriction [29, 30, 
50–55] suggest rMETase is a general therapeutic for 
all cancer. Extensive safety tests were performed with 
rMETase in primates [56, 57] and initial testing in 
humans [58, 59] indicated minimal toxicity of rMETase. 
Very recently we have shown that rMETase can be 
administered orally [24], suggesting the near-future 
widespread use of rMETase for all types of cancer in the 
clinic. 
Methionine dependence is due to the overuse of 
methionine for aberrant transmethylation reactions in 
cancer and is possibly the only known general metabolic 
defect in cancer [50, 60–66]. 
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Figure 1: Treatment schema.
Figure 2: In vivo antitumor efficacy of doxorubicin (DOX), l-methionine α-deamino-γ-mercaptomethane lyase 
(rMETase) and DOX combined with rMETase. Synovial sarcoma was grown orthotopically in the right biceps femoris muscle of 
nude mice and allowed to form tumors. Treatment, dose, route, and schedule were: DOX (3 mg/kg/week i.p. for 2 weeks), and rMETase 
(100 U/mouse/day, i.p., for 14 days). Relative tumor volume, shown by the line graphs, is the tumor volume at the indicated time points 
during the time of treatment divided by the tumor volume at the onset of treatment. N = 8 mice/group. *p < 0.05, **p < 0.001.
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Figure 3: Photos of representative treated and untreated SS PDOX tumor.
Figure 4: Bar graph shows body weight in each group at pre-treatment and 2 weeks after drug administration. There 
were no significant differences between any group.
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The overuse of methionine by cancer cells for 
enhanced and unbalanced transmethylation may be 
the basis of the methionine dependence of cancer cells 
and is termed the “Hoffman effect”, analogous to the 
Warburg effect of glucose overuse in cancer [64]. The 
Hoffman effect can be observed clinically in [11C]MET 
PET imaging which gives a much stronger signal than 
fluorodeoxyglucose (FDG)-PET [67]. 
Previously-developed concepts and strategies of 
highly-selective tumor targeting can take advantage of 
Figure 5: Tumor histology. (A) H&E-stained section of the original SS patient tumor; (B) untreated SS PDOX tumor; (C) SS PDOX 
tumor treated with DOX; (D) SS PDOX tumor treated with rMETase and (E) SS PDOX tumor treated with DOX combined with rMETase. 
White scale bars: 50 µm.
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molecular targeting of tumors, including tissue-selective 
therapy which focuses on unique differences between 
normal and tumor tissues [68–73].
MATERIALS AND METHODS
Mice
Athymic nu/nu male nude mice (AntiCancer, 
Inc., San Diego, CA), 4–6 weeks old, were used in this 
study. All mice were kept in a barrier facility on a high 
efficiency particulate arrestance (HEPA)-filtered rack 
under standard conditions of 12-hour light/dark cycles. 
The animals were fed an autoclaved laboratory rodent 
diet. All animal experiments were performed with an 
AntiCancer Institutional Animal Care and Use Committee 
(IACUC)-protocol specifically approved for this study and 
in accordance with the principals and procedures outlined 
in the National Institutes of Health Guide for the Care 
and Use of Animals under Assurance Number A3873-
1. Anesthesia and analgesics were used for all surgical 
experiments to avoid excessive suffering of the mice. A 
ketamine mixture (0.02 ml solution of 20 mg/kg ketamine, 
15.2 mg/kg xylazine, and 0.48 mg/kg acepromazine 
maleate) was used subcutaneously for all mice. The 
animals were monitored carefully during surgery to keep 
adequate depth of anesthesia. The animals were observed 
daily and humanely sacrificed by CO2 inhalation when 
they met the following criteria: severe tumor burden 
(more than 20 mm in diameter), prostration, significant 
body weight loss, difficulty breathing, rotational motion 
and body temperature drop.
Patient-derived tumor
A 45-year-old male diagnosed with primary synovial 
sarcoma on the lower leg underwent surgical resection at 
the Department of Surgery, University of California, Los 
Angeles (UCLA). Written informed consent was obtained 
from the patient as part of a UCLA Institutional Review 
Board (IRB #10-001857)-approved protocol. The patient 
received neo-adjuvant doxorubicin-based chemotherapy 
prior to surgery.
Surgical orthotopic implantation (SOI) for 
establishment of PDOX model
A fresh sample of the tumor of the patient was 
obtained and transported immediately to the laboratory 
at AntiCancer, Inc., on wet ice. The sample was cut into 
5 mm fragments and initially implanted subcutaneously 
in nude mice. The grown tumors were cut into small 
fragments (3–4 mm). After nude mice were anesthetized, 
a 5 mm skin incision was made on the right high thigh, 
and biceps femoris was split to make space for the tumor. 
A single tumor fragment was implanted orthotopically 
into the space to establish a PDOX model. The wound 
was closed with 6-0 nylon suture (Ethilon, Ethicon, Inc., 
NJ, USA).
rMETase production
The pAC-1 rMETase high-expression clone was 
used for rMETase production. The fermentation procedure 
for host E.coli cells and the purification protocol for 
rMETase were the same as previously described: rMETase 
was purified by 3 different steps using columns of DEAE 
Sepharose FF, Sephacryl S-200HR, and ActiClean Etox, 
which is designed for eliminating endotoxin [74].
Treatment study design in the PDOX model of 
synovial sarcoma
SS PDOX mouse models were randomized into 
4 groups of 8 mice each: G1, control without treatment; 
G2, Doxorubicin (DOX) (3 mg/kg, intraperitoneal [i.p.] 
injection, weekly, for 2 weeks); G3, rMETase (100 unit/
mouse, i.p., daily, for 2 weeks); G4, DOX (3 mg/kg), i.p. 
weekly, for 2 weeks) combined with rMETase (100 unit/
mouse, i.p., daily, for 2 weeks) (Figure 1). Tumor length, 
width and mouse body weight were measured twice in a 
week. Tumor volume was calculated with the following 
formula: Tumor volume (mm3) = length (mm) × width (mm) 
× width (mm) × 1/2. Data are presented as mean ± SD. 
Histological examination
Fresh tumor samples were fixed in 10% formalin 
and embedded in paraffin before sectioning and staining. 
Tissue sections (3 μm) were deparaffinized in xylene and 
rehydrated in an ethanol series. Hematoxylin and eosin 
(H&E) staining was performed according to standard 
protocol. Histological examination was performed with 
a BHS system microscope. Images were acquired with 
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